These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6686849)

  • 1. Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.
    Fuks JZ; Aisner J; Van Echo DA; Schipper H; Levitt M; Ostrow S; Wiernik PH
    J Clin Oncol; 1983 May; 1(5):295-301. PubMed ID: 6686849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.
    Bunn PA; Greco FA; Einhorn L
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):45-53. PubMed ID: 3020700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study.
    Valdivieso M; Burgess MA; Ewer MS; Mackay B; Wallace S; Benjamin RS; Ali MK; Bodey GP; Freireich EJ
    J Clin Oncol; 1984 Mar; 2(3):207-14. PubMed ID: 6321689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cisplatin, cyclophosphamide, vincristine, and doxorubicin for the treatment of non-small cell lung cancer.
    Lindgren D; Cadman E; Erichson R; Grann V; Sachs K
    Cancer Treat Rep; 1984 Sep; 68(9):1159-61. PubMed ID: 6090015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.
    Joss RA; Alberto P; Obrecht JP; Barrelet L; Holdener EE; Siegenthaler P; Goldhirsch A; Mermillod B; Cavalli F
    Cancer Treat Rep; 1984 Sep; 68(9):1079-84. PubMed ID: 6090014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
    Roth BJ; Johnson DH; Einhorn LH; Schacter LP; Cherng NC; Cohen HJ; Crawford J; Randolph JA; Goodlow JL; Broun GO
    J Clin Oncol; 1992 Feb; 10(2):282-91. PubMed ID: 1310103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study.
    Wampler GL; Heim WJ; Ellison NM; Ahlgren JD; Fryer JG
    J Clin Oncol; 1991 Aug; 9(8):1438-45. PubMed ID: 1649265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adriamycin, cisplatin and etoposide combination chemotherapy in non-small cell lung cancer].
    Yamaji Y; Fujita J; Kamei M; Futami H; Hashimoto Y; Bungo M; Nakamura H; Hata Y; Shiotani T; Irino S
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):601-6. PubMed ID: 1849390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Curcio A; Vola F; Mattalia E
    Chemioterapia; 1986 Feb; 5(1):53-7. PubMed ID: 3955784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.
    Messeih AA; Schweitzer JM; Lipton A; Harvey HA; Simmonds MA; Stryker JA; Ricci JA; Hoffman SL; Gottleib RJ; Dixon RH
    Cancer Treat Rep; 1987 Jan; 71(1):61-6. PubMed ID: 3024828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
    Lelli G; Casadio M; Giuliotti C; Giordani S; Martoni A; Strocchi E; Pannuti F
    Chemioterapia; 1986 Aug; 5(4):228-31. PubMed ID: 3021346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
    Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin.
    Dhingra HM; Valdivieso M; Booser DJ; Umsawasdi T; Carr DT; Chiuten DF; Murphy WK; Issell BF; Spitzer G; Farha P
    Cancer Treat Rep; 1984 Apr; 68(4):671-3. PubMed ID: 6538811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer.
    Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L
    Cancer Treat Rep; 1982 Dec; 66(12):2005-11. PubMed ID: 6291763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.